secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117650
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Q3 net loss $6.0M vs $1.2M YoY; cash down to $4.0M; CEO change and $7.4M PIPE closed
--------------------------------------------------------------------------------

- Net loss of $6.0M for Q3 2022, up from $1.2M in Q3 2021; R&D expenses rose to $4.6M from $0.8M.
- Cash and equivalents $4.0M at Sep 30, 2022, down from $17.0M at Dec 31, 2021; Oct 2022 PIPE netted $6.4M.
- Gail Farfel appointed CEO effective Sep 19, 2022; co-founder Eugene Williams remains Chairman.
- IND submission for Alzheimer's candidate PMN310 progressing; first subject enrollment expected H1 2023.
- ALS candidate PMN267 and MSA candidate PMN442 advancing; vaccine program ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465922117650/0001104659-22-117650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465922117650/tm2224043d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer